| |
|
NASH | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| 1. | Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis |
| |
Hepatology. 2020 May 16.doi: 10.1002/hep.31317. Online ahead of print.
Kimberly P Newton 1 2, Joel E Lavine 3, Laura Wilson 4 5, Cynthia Behling 6 7, Miriam B Vos 8, Jean P Molleston 9, Philip Rosenthal 10, Tamir Miloh 11, Mark H Fishbein 12, Ajay K Jain 13, Karen F Murray 14, Jeffrey B Schwimmer 1 2, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN):
Donna Garner, Paula Hertel, Ryan Himes, Alicia Lawson, Tamir Miloh, Nicole Triggs, Kristin Bramlage, April Carr, Kim Cecil, Meghan McNeill, Marialena Mouzaki, Andrew Trout, Stavra Xanthakos, Kimberlee Bernstein, Stephanie DeVore, Rohit Kohli, Kathleen Lake, Daniel Podberesky, Alex Towbin, Joel E Lavine, Ali Mencin, Elena Reynoso, Adina Alazraki, Rebecca Cleeton, Maria Cordero, Albert Hernandez, Saul Karpen, Jessica Cruz Munos, Nicholas Raviele, Miriam Vos, Molly Bozic, Laura Carr, Oscar W Cummings, Kathryn Harlow, Ann Klipsch, Jean P Molleston, Emily Ragozzino, Girish Rao, Kimberly Kafka, Ann Scheimann, Mark H Fishbein, Saeed Mohammad, Peter F Whitington, Sarah Barlow, Elizabeth M Brunt, Danielle Carpenter, Theresa Cattoor, Jose Derdoy, Janet Freebersyser, Ajay Jain Debra King, Jinping Lai, Joan Siegner, Susan Stewart, Susan Torretta, Kristina Wriston, Jennifer Arin, Cynthia Behling, Craig Bross, Carissa Carrier, Diana De La Pena, Janis Durelle, Mary Catherine Huckaby, Michael S Middleton, Kimberly Newton, Jeffrey B Schwimmer, Claude Sirlin, Patricia Ugalde-Nicalo, Jesse Courtier, Ryan Gill, Camille Langlois, Emily Rothbaum Perito, Philip Rosenthal, Patrika Tsai, Niviann Blondet, Kara Cooper, Karen Murray, Randolph Otto, Matthew Yeh, Melissa Young, Elizabeth M Brunt, Kathryn Fowler, David E Kleiner, Edward C Doo, Sherry Hall, Jay H Hoofnagle, Patricia R Robuck, Averell H Sherker, Rebecca Torrance, Patricia Belt, Jeanne M Clark, John Dodge, Michele Donithan, Milana Isaacson, Mariana Lazo, Jill Meinert, Laura Miriel, Emily P Sharkey, Jacqueline Smith, Michael Smith, Alice Sternberg, James Tonascia, Mark L Van Natta, Annette Wagoner, Laura A Wilson, Goro Yamada, Katherine P Yates
|
|
| |
|
|
| |
|
|
| |
| 4. | Non-alcoholic Liver Disease and Childhood Obesity |
| |
Arch Dis Child. 2020 May 14;archdischild-2019-318063.doi: 10.1136/archdischild-2019-318063. Online ahead of print.
Meera Shaunak 1, Christopher D Byrne 2 3, Nikki Davis 1 2, Paul Afolabi 2 3, Saul N Faust 2 3 4, Justin Huw Davies 5 2
|
|
| |
|
|
| |
| 6. | Risk Stratification of Patients With Nonalcoholic Fatty Liver Disease Using a Case Identification Pathway in Primary Care: A Cross-Sectional Study |
| |
MAJ Open. 2020 May 15;8(2):E370-E376.doi: 10.9778/cmajo.20200009. Print Apr-Jun 2020.
Abdel Aziz Shaheen 1, Kiarash Riazi 2, Alexandra Medellin 2, Deepak Bhayana 2, Gilaad G Kaplan 2, Jason Jiang 2, Roy Park 2, Wendy Schaufert 2, Kelly W Burak 2, Monica Sargious 2, Mark G Swain 2
|
|
| |
|
|
| |
| 8. | Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis |
| |
Clin Gastroenterol Hepatol. 2020 Apr 30;S1542-3565(20)30613-3.doi: 10.1016/j.cgh.2020.04.068. Online ahead of print.
Fateh Bazerbachi 1, Eric J Vargas 2, Monika Rizk 2, Daniel B Maselli 2, Taofic Mounajjed 3, Sudhakar K Venkatesh 4, Kymberly D Watt 2, John D Port 4, Rita Basu 5, Andres Acosta 2, Ibrahim Hanouneh 2, Naveen Gara 6, Meera Shah 7, Manpreet Mundi 7, Matthew Clark 7, Karen Grothe 7, Andrew C Storm 2, Michael J Levy 2, Barham K Abu Dayyeh 8
|
|
| |
| 9. | Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis |
| |
Immunity. 2020 May 1;S1074-7613(20)30159-X. doi: 10.1016/j.immuni.2020.04.001.Online ahead of print.
Jason S Seidman 1, Ty D Troutman 2, Mashito Sakai 1, Anita Gola 3, Nathanael J Spann 1, Hunter Bennett 1, Cassi M Bruni 1, Zhengyu Ouyang 1, Rick Z Li 1, Xiaoli Sun 4, BaoChau T Vu 1, Martina P Pasillas 1, Kaori M Ego 1, David Gosselin 5, Verena M Link 6, Ling-Wa Chong 7, Ronald M Evans 8, Bonne M Thompson 9, Jeffrey G McDonald 9, Mojgan Hosseini 10, Joseph L Witztum 4, Ronald N Germain 3, Christopher K Glass 11
|
|
| |
|
|
| |
| 11. | Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum |
| |
J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9 doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.
Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
|
|
| |
|
|
| |
| 13. | Biomarkers of NAFLD and NASH |
| |
Metabolism. 2020 May 5;154259. doi: 10.1016/j.metabol.2020.154259.Online ahead of print.
Michelle T Long 1, Sanil Gandhi 2, Rohit Loomba 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 29. | Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations From the Liver Forum |
| |
J Hepatol. 2020 Apr 27;S0168-8278(20)30274-9. doi: 10.1016/j.jhep.2020.04.030.Online ahead of print.
Oliver Glass 1, Claudia Filozof 2, Mazen Noureddin 3, Mark Berner-Hansen 4, Elmer Schabel 5, Stephanie O Omokaro 6, Jörn M Schattenberg 7, Katherine Barradas 8, Veronica Miller 8, Sven Francque 9, Manal F Abdelmalek 10, Liver Forum Standard of Care Working Group
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 37. | Bile acids associate with specific gut microbiota, low level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease |
| |
Adams LA1,2, Wang Z1,2, Liddle C3, Melton PE4,5, Ariff A4, Chandraratna H6, Tan J7, Ching H1, Coulter S3, de Boer B8, Christophersen CT9,10, O'Sullivan TA9, Morrison M11, Jeffrey GP1,2. Liver Int. 2020 Apr 3. doi: 10.1111/liv.14453. [Epub ahead of print]
|
|
| |
| 38. | Dietary Factors in Relation to Liver Fat Content: A Cross-sectional Study |
| |
Watzinger C1, Nonnenmacher T2, Grafetstätter M1, Sowah SA1,3, Ulrich CM4, Kauczor HU2, Kaaks R1, Schübel R1,2, Nattenmüller J2, Kühn T1. Nutrients. 2020 Mar 20;12(3). pii: E825. doi: 10.3390/nu12030825.
|
|
| |
|
|
| |
| 40. | Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study |
| |
Newsome PN1, Palmer M2, Freilich B3, Sheikh MY4, Sheikh A5, Sarles H6, Herring R7, Mantry P8, Kayali Z9, Hassanein T10, Lee HM2, Aithal GP11; Volixibat in Adults study group. J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186-0. doi: 10.1016/j.jhep.2020.03.024. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 49. | Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk |
| |
Han E1, Lee YH2,3, Kim YD4, Kim BK2,5,6, Park JY2,5,6, Kim DY2,5,6, Ahn SH2,5,6, Lee BW2,3, Kang ES2,3, Cha BS2,3, Han KH2,5,6, Nam HS4, Heo JH4, Kim SU2,5,6. Am J Gastroenterol. 2020 Mar 3. doi: 10.14309/ajg.0000000000000572. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 53. | Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials |
| |
Harrison SA1, Wai-Sun Wong V2, Okanoue T3, Bzowej N4, Vuppalanchi R5, Younes Z6, Kohli A7, Sarin S8, Caldwell SH9, Alkhouri N10, Shiffman ML11, Camargo M12, Li G12, Kersey K12, Jia C12, Zhu Y12, Djedjos CS12, Subramanian GM12, Myers RP12, Gunn N13, Sheikh A14, Anstee QM15, Romero-Gomez M16, Trauner M17, Goodman Z18, Lawitz EJ10, Younossi Z18; STELLAR-3 and STELLAR-4 Investigators. J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126-4. doi: 10.1016/j.jhep.2020.02.027. [Epub ahead of print]
|
|
| |
| 54. | Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial |
| |
Patel K1, Harrison SA2, Elkashab M3, Trotter JF4, Herring R5, Rojter S6, Kayali Z7, Wong VW8, Greenbloom S9, Jayakumar S10, Shiffman ML11, Freilich B12, Lawitz EJ, Gane E13,14, Harting E15, Xu J15, Billin AN15, Chung C15, Djedjos CS15, Subramanian GM15, Myers RP15, Middleton MS10, Rinella M16, Noureddin M17. Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 59. | A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic LiverDisease Mainly Due to NAFLD |
| |
Dong TS1, Katzka W1,2, Lagishetty V1,2, Luu K1,2, Hauer M1,2, Pisegna J3, Jacobs JP4,5,6. Sci Rep. 2020 Feb 17;10(1):2771. doi: 10.1038/s41598-020-59535-w.
|
|
| |
| 60. | Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study |
| |
VanWagner LB1,2, Wilcox JE2,3, Ning H2, Lewis CE4, Carr JJ5, Rinella ME1, Shah SJ3, Lima JAC6, Lloyd-Jones DM2,3. J Am Heart Assoc. 2020 Feb 18;9(4):e014279. doi: 10.1161/JAHA.119.014279. Epub 2020 Feb 6.
|
|
| |
|
|
| |
|
|
| |
| 63. | A diabetologist |
| |
Cusi K1,2. Liver Int. 2020 Feb;40 Suppl 1:82-88. doi: 10.1111/liv.14350.
|
|
| |
|
|
| |
| 65. | New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent? |
| |
Guaraldi G1, Maurice JB2, Marzolini C3, Monteith K4, Milic J1, Tsochatzis E5, Bhagani S6, Morse CG7, Price JC8, Ingiliz P9,10, Lemoine M11, Sebastiani G12; SHIVER Network. Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177. [Epub ahead of print]
|
|
| |
| 66. | The association of nonalcoholic steatohepatitis and hepatocellular carcinoma |
| |
Asfari MM1,2, Talal Sarmini M2, Alomari M2, Lopez R3, Dasarathy S4,5,6, McCullough AJ4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 82. | Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis |
| |
Taylor RS1, Taylor RJ2, Bayliss S3, Hagstrom H4, Nasr P5, Schattenberg JM6, Ishigami M7, Toyoda H8, Wai-Sun Wong V9, Peleg N10, Shlomai A11, Sebastiani G12, Seko Y13, Bhala N14, Younossi ZM15, Anstee QM16, McPherson S17, Newsome PN18; Collaborators. Gastroenterology. 2020 Feb 3. pii: S0016-5085(20)30137-2. doi: 10.1053/j.gastro.2020.01.043. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 85. | Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study |
| |
Ratziu V1, Sanyal A2, Harrison SA3, Wong VW4, Francque S5, Goodman Z6, Aithal GP7, Kowdley KV8, Seyedkazemi S9, Fischer L9, Loomba R10,11, Abdelmalek MF12, Tacke F13,14. Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]
|
|
| |
| 86. | Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis |
| |
Loomba R1, Neuschwander-Tetri BA2, Sanyal A3, Chalasani N4, Diehl AM5, Terrault N6, Kowdley K7, Dasarathy S8, Kleiner D9, Behling C1, Lavine J10, Van Natta M11, Middleton M1, Tonascia J11, Sirlin C1; NASH Clinical Research Network. Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]
|
|
| |
|
|
| |
| 88. | Multiparametric Magnetic Resonance Elastography Improves the Detection of NASHRegression Following Bariatric Surgery |
| |
Allen AM1, Shah VH1, Therneau TM2, Venkatesh SK3, Mounajjed T4, Larson JJ2, Mara KC2, Kellogg TA5, Kendrick ML5, McKenzie TJ5, Greiner SM1, Li J3, Glaser KJ3, Wells ML3, Gunneson TJ6, Ehman RL3, Yin M3. Hepatol Commun. 2019 Nov 5;4(2):185-192. doi: 10.1002/hep4.1446. eCollection 2020 Feb.
|
|
| |
| 89. | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study |
| |
Newsome PN1, Sasso M2, Deeks JJ3, Paredes A4, Boursier J5, Chan WK6, Yilmaz Y7, Czernichow S8, Zheng MH9, Wong VW10, Allison M11, Tsochatzis E12, Anstee QM13, Sheridan DA14, Eddowes PJ15, Guha IN15, Cobbold JF16, Paradis V17, Bedossa P18, Miette V2, Fournier-Poizat C19, Sandrin L2, Harrison SA20. Lancet Gastroenterol Hepatol. 2020 Feb 3. pii: S2468-1253(19)30383-8. doi: 10.1016/S2468-1253(19)30383-8. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 94. | Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease |
| |
Scorletti E1, Afolabi PR2, Miles EA3, Smith DE2, Almehmadi A3, Alshathry A3, Childs CE3, Del Fabbro S3, Beavis J3, Moyses HE4, Clough GF3, Sethi JK5, Patel J6, Wright M6, Breen DJ7, Peebles C7, Darekar A8, Aspinall R9, Fowell AJ9, Dowman JK9, Nobili V10, Targher G11, Delzenne NM12, Bindels LB12, Calder PC13, Byrne CD2. Gastroenterology. 2020 Jan 24. pii: S0016-5085(20)30124-4. doi: 10.1053/j.gastro.2020.01.031. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 98. | Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack |
| |
Oates JR1,2,3, McKell MC1,3,4, Moreno-Fernandez ME1,2, Damen MSMA1,2, Deepe GS Jr5, Qualls JE1,3,4, Divanovic S1,2,3,6. Front Immunol. 2019 Dec 12;10:2893. doi: 10.3389/fimmu.2019.02893. eCollection 2019.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 102. | A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression |
| |
Delacôte C1, Bauvin P1, Louvet A2, Dautrecque F3, Ntandja Wandji LC3, Lassailly G2, Voican C4, Perlemuter G4, Naveau S4, Mathurin P2, Deuffic-Burban S5. Clin Gastroenterol Hepatol. 2020 Jan 10. pii: S1542-3565(20)30039-2. doi: 10.1016/j.cgh.2019.12.041. [Epub ahead of print]
|
|
| |
|
|
| |
| 104. | Continued muscle loss increases mortality in cirrhosis- impact of etiology of liver disease |
| |
Welch N1,2, Dasarathy J3, Runkana A4, Penumatsa R2, Bellar A2, Reen J2, Rotroff D5, McCullough AJ1, Dasarathy S1,2. Liver Int. 2019 Dec 31. doi: 10.1111/liv.14358. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 107. | Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression |
| |
Du K1, Chitneni SK2, Suzuki A1, Wang Y1, Henao R3, Hyun J1, Premont RT1, Naggie S4, Moylan CA1, Bashir MR5, Abdelmalek MF1, Diehl AM6. Cell Mol Gastroenterol Hepatol. 2019 Dec 24. pii: S2352-345X(19)30182-1. doi: 10.1016/j.jcmgh.2019.12.006. [Epub ahead of print]
|
|
| |
| 108. | A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis |
| |
Harrison SA1, Goodman Z2, Jabbar A3, Vemulapalli R4, Younes ZH5, Freilich B6, Sheikh MY7, Schattenberg JM8, Kayali Z9, Zivony A10, Sheikh A11, Garcia-Samaniego J12, Satapathy SK13, Therapondos G14, Mena E15, Schuppan D16, Robinson J17, Chan JL17, Hagerty DT18, Sanyal AJ19. J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]
|
|
| |
| 109. | A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH |
| |
Gawrieh S1, Guo X2, Tan J2, Lauzon M2, Taylor KD2, Loomba R3, Cummings OW4, Pillai S5, Bhatnagar P5, Kowdley KV6, Yates K7, Wilson LA7, Chen YI2, Rotter JI2, Chalasani N1; NASH Clinical Research Network. Hepatol Commun. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 113. | Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension |
| |
Zhao YC1,2, Zhao GJ1,2, Chen Z1,2, She ZG1,2,3,4, Cai J1,5,2, Li H1,2,3. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419. Epub 2019 Dec 23.
|
|
| |
| 114. | Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic FattyLiver Disease in Patients With Crohn |
| |
McHenry S1, Tirath A2, Tsai R3, Sharma Y4, Flores AG1, Davidson NO1, Fowler KJ3,5, Ciorba MA1,4, Deepak P1,6. Inflamm Bowel Dis. 2020 Jan 7. pii: izz324. doi: 10.1093/ibd/izz324. [Epub ahead of print]
|
|
| |
|
|
| |
| 116. | Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension |
| |
Garcia-Tsao G1, Bosch J2, Kayali Z3, Harrison SA4, Abdelmalek MF5, Lawitz E6, Satapathy SK7, Ghabril M8, Shiffman ML9, Younes ZH10, Thuluvath PJ11, Berzigotti A12, Albillos A13, Robinson JM14, Hagerty DT14, Chan JL14, Sanyal AJ15; IDN-6556-14 Investigators. J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 123. | Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease |
| |
Danford CJ1, Jiang ZG1, Salomaa V2, Färkkilä M3, Jula A2, Männistö S2, Lundqvist A2, Valsta L2, Perola M2, Åberg F4,5. Hepatol Commun. 2019 Oct 10;3(12):1704-1705. doi: 10.1002/hep4.1437. eCollection 2019 Dec.
|
|
| |
| 124. | Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features |
| |
Bullón-Vela V1, Abete I2, Tur JA3, Pintó X4, Corbella E4, Martínez-González MA5, Toledo E5, Corella D6, Macías M7, Tinahones F7, Fitó M8, Estruch R9, Ros E10, Salas-Salvadó J11, Daimiel L12, Zulet MA13, Martínez JA2; PREDIMED Plus investigators. Nutrition. 2019 Oct 25;71:110620. doi: 10.1016/j.nut.2019.110620. [Epub ahead of print]
|
|
| |
| 125. | Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity |
| |
Peña-Vélez R1,2, Garibay-Nieto N1,2,3, Cal-Y-Mayor-Villalobos M4, Laresgoiti-Servitje E5, Pedraza-Escudero K1,2, García-Blanco MDC4, Heredia-Nieto OA6, Villanueva-Ortega E1,2. J Pediatr Endocrinol Metab. 2019 Dec 16. pii: /j/jpem.ahead-of-print/jpem-2019-0204/jpem-2019-0204.xml. doi: 10.1515/jpem-2019-0204. [Epub ahead of print]
|
|
| |
|
|
| |
| 127. | Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered |
| |
Plaz Torres MC1,2,3, Aghemo A3,4, Lleo A3,4, Bodini G1,2,3, Furnari M1, Marabotto E1, Miele L5, Giannini EG1,2,6. Nutrients. 2019 Dec 5;11(12). pii: E2971. doi: 10.3390/nu11122971.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 131. | Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis |
| |
Siddiqui MS1, Van Natta ML2, Connelly MA3, Vuppalanchi R4, Neuschwander-Tetri BA5, Tonascia J2, Guy C6, Loomba R7, Dasarathy S8, Wattacheril J9, Chalasani N4, Sanyal AJ10; NASH CRN. J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607-5. doi: 10.1016/j.jhep.2019.10.006. [Epub ahead of print]
|
|
| |
| 132. | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development |
| |
Mouries J1, Brescia P1, Silvestri A1, Spadoni I2, Sorribas M3, Wiest R4, Mileti E5, Galbiati M6, Invernizzi P6, Adorini L7, Penna G8, Rescigno M9. J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
|
|
| |
| 133. | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis |
| |
Ratziu V1, Sanyal AJ2, Loomba R3, Rinella M4, Harrison S5, Anstee QM6, Goodman Z7, Bedossa P8, MacConell L9, Shringarpure R9, Shah A9, Younossi Z7. Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.
|
|
| |
| 134. | Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis |
| |
Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.
|
|
| |
| 135. | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial |
| |
Younossi ZM1, Ratziu V2, Loomba R3, Rinella M4, Anstee QM5, Goodman Z1, Bedossa P6, Geier A7, Beckebaum S8, Newsome PN9, Sheridan D10, Sheikh MY11, Trotter J12, Knapple W13, Lawitz E14, Abdelmalek MF15, Kowdley KV16, Montano-Loza AJ17, Boursier J18, Mathurin P19, Bugianesi E20, Mazzella G21, Olveira A22, Cortez-Pinto H23, Graupera I24, Orr D25, Gluud LL26, Dufour JF27, Shapiro D28, Campagna J28, Zaru L28, MacConell L28, Shringarpure R28, Harrison S29, Sanyal AJ30; REGENERATE Study Investigators.
Collaborators (336) Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]
|
|
| |
| 136. | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes |
| |
Poynard T1,2, Peta V2,3, Deckmyn O3, Pais R1,2, Ngo Y2,3, Charlotte F4, Ngo A3, Munteanu M2,3, Imbert-Bismut F5, Monneret D5, Housset C2, Thabut D1,2, Valla D6, Boitard C7, Castera L6, Ratziu V1; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group.
|
|
| |
|
|
| |
| 138. | Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany |
| |
Labenz C1,2, Huber Y1,2, Michel M1,2, Nagel M1,2, Galle PR1,2, Kostev K3, Schattenberg JM4,5. Dig Dis Sci. 2019 Dec 3. doi: 10.1007/s10620-019-05986-9. [Epub ahead of print]
|
|
| |
|
|
| |
| 140. | Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease |
| |
Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. J Clin Invest. 2019 Dec 5. pii: 134165. doi: 10.1172/JCI134165. [Epub ahead of print]
|
|
| |
| 141. | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. |
| |
Pedrosa M1, Seyedkazemi S2, Francque S3, Sanyal A4, Rinella M5, Charlton M6, Loomba R7, Ratziu V8, Kochuparampil J1, Fischer L2, Vaidyanathan S9, Anstee QM10. Contemp Clin Trials. 2019 Nov 13;88:105889. doi: 10.1016/j.cct.2019.105889. [Epub ahead of print]
|
|
| |
| 142. | Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease |
| |
Shili-Masmoudi S1, Wong GL2,3, Hiriart JB1, Liu K4,5, Chermak F1, Shu SS2,3, Foucher J1, Tse YK2,3, Bernard PH1, Yip TC2,3, Merrouche W1, Chan HL2,3, Wong VW2,3, de Lédinghen V1,6. Liver Int. 2019 Nov 20. doi: 10.1111/liv.14301. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 150. | GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis |
| |
Best J1, Bechmann LP1, Sowa JP1, Sydor S1, Dechêne A2, Pflanz K3, Bedreli S3, Schotten C3, Geier A4, Berg T5, Fischer J5, Vogel A6, Bantel H6, Weinmann A7, Schattenberg JM7, Huber Y7, Wege H8, von Felden J8, Schulze K8, Bettinger D9, Thimme R10, Sinner F1, Schütte K1, Weiss KH11, Toyoda H12, Yasuda S12, Kumada T13, Berhane S14, Wichert M15, Heider D16, Gerken G3, Johnson P14, Canbay A17. Clin Gastroenterol Hepatol. 2019 Nov 8. pii: S1542-3565(19)31267-4. doi: 10.1016/j.cgh.2019.11.012. [Epub ahead of print]
|
|
| |
| 151. | Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| |
Harrison SA1, Bashir MR2, Guy CD2, Zhou R3, Moylan CA2, Frias JP4, Alkhouri N5, Bansal MB6, Baum S7, Neuschwander-Tetri BA8, Taub R9, Moussa SE10. Lancet. 2019 Nov 11. pii: S0140-6736(19)32517-6. doi: 10.1016/S0140-6736(19)32517-6. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 155. | Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study |
| |
Harrison SA1, Alkhouri N2, Davison BA3, Sanyal A4, Edwards C3, Colca JR5, Lee BH5, Loomba R6, Cusi K7, Kolterman O8, Cotter G3, Dittrich HC5. J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]
|
|
| |
|
|
| |
| 157. | Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease |
| |
Kanwal F1,2,3, Kramer J2,3, Li L4, Dai J4, Natarajan Y1, Yu X2,3, Asch SM5,6, El-Serag HB1,2,3. Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014. [Epub ahead of print]
|
|
| |
| 158. | A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health |
| |
Moolla A1,2, Motohashi K1, Marjot T1,3, Shard A3, Ainsworth M3, Gray A4, Holman R2,5, Pavlides M2,3, Ryan JD2,3, Tomlinson JW1,2, Cobbold JF2,3. Frontline Gastroenterol. 2019 Oct;10(4):337-346. doi: 10.1136/flgastro-2018-101155. Epub 2019 Apr 30.
|
|
| |
|
|
| |
| 160. | Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol |
| |
Labenz C1, Prochaska JH2,3,4, Huber Y1, Nagel M1, Straub BK5, Wild P2,3,4, Galle PR1, Schattenberg JM1,6. Hepatol Commun. 2019 Sep 30;3(11):1472-1481. doi: 10.1002/hep4.1428. eCollection 2019 Nov.
|
|
| |
|
|
| |
| 162. | Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial |
| |
Navarro VJ1, Belle SH2, D'Amato M3, Adfhal N4, Brunt EM5, Fried MW6, Reddy KR7, Wahed AS2, Harrison S8; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. PLoS One. 2019 Sep 19;14(9):e0221683. doi: 10.1371/journal.pone.0221683. eCollection 2019.
|
|
| |
| 163. | Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients |
| |
Sebastiani G1,2, Saeed S3, Lebouche B1, de Pokomandy A1, Szabo J1, Haraoui LP1, Routy JP1,4, Wong P2, Deschenes M2, Ghali P2, Klein M1; LIVEHIV Study Group. AIDS. 2019 Oct 16. doi: 10.1097/QAD.0000000000002412. [Epub ahead of print]
|
|
| |
|
|
| |
| 165. | Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease |
| |
Seth A1, Orkin S2, Yodoshi T2, Liu C3, Fei L3, Hardy J2, Trout AT4, Arce Clachar AC2, Bramlage K2, Xanthakos S2, Mouzaki M2. Pediatr Obes. 2019 Oct 27. doi: 10.1111/ijpo.12581. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 176. | Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial |
| |
Stanley TL1, Fourman LT1, Feldpausch MN1, Purdy J2, Zheng I1, Pan CS1, Aepfelbacher J2, Buckless C3, Tsao A3, Kellogg A4, Branch K5, Lee H6, Liu CY7, Corey KE8, Chung RT8, Torriani M3, Kleiner DE9, Hadigan CM2, Grinspoon SK10. Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 179. | Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults |
| |
Alexander M1, Loomis AK2, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6,7, Pasqua A8, Lapi F8, Rijnbeek P3, Mosseveld M3, Avillach P3,9, Egger P1, Dhalwani NN10, Kendrick S11, Celis-Morales C12, Waterworth DM13, Alazawi W14, Sattar N12. BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.
|
|
| |
|
|
| |
| 181. | A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe |
| |
Lazarus JV1, Ekstedt M2, Marchesini G3, Mullen J4, Novak K5, Pericàs JM6, Roel E7, Romero-Gómez M8, Ratziu V9, Tacke F10, Cortez-Pinto H11, Anstee QM12; EASL International Liver Foundation NAFLD Policy Review Collaborators. J Hepatol. 2019 Sep 10. pii: S0168-8278(19)30521-5. doi: 10.1016/j.jhep.2019.08.027. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 187. | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life |
| |
Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Oct;114(10):1636-1641. doi: 10.14309/ajg.0000000000000375.
|
|
| |
|
|
| |
|
|
| |
| 190. | Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liverdisease in the United States |
| |
Adejumo AC1,2,3,4, Samuel GO5, Adegbala OM6, Adejumo KL4, Ojelabi O3, Akanbi O7, Ogundipe OA8, Pani L1,2. Ann Gastroenterol. 2019 Sep-Oct;32(5):504-513. doi: 10.20524/aog.2019.0402. Epub 2019 Jul 17.
|
|
| |
| 191. | Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic FattyLiver Disease Who Have Normal Aminotransferase Levels |
| |
Gawrieh S1, Wilson LA2, Cummings OW3, Clark JM2, Loomba R4, Hameed B5, Abdelmalek MF6, Dasarathy S7, Neuschwander-Tetri BA8, Kowdley K9, Kleiner D10, Doo E11, Tonascia J2, Sanyal A12, Chalasani N1; and the NASH Clinical Research Network. Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.
|
|
| |
| 192. | Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study |
| |
Gawrieh S1, Dakhoul L1, Miller E2, Scanga A3, deLemos A4, Kettler C1, Burney H1, Liu H1, Abu-Sbeih H2, Chalasani N1, Wattacheril J5. Aliment Pharmacol Ther. 2019 Oct;50(7):809-821. doi: 10.1111/apt.15464. Epub 2019 Sep 1.
|
|
| |
|
|
| |
| 194. | Multi-drug approaches to NASH: what |
| |
Johnston MP1, Patel J1, Byrne CD2,3. Expert Opin Investig Drugs. 2019 Sep 23:1-8. doi: 10.1080/13543784.2020.1668926. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 199. | HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease |
| |
McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 204. | HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease |
| |
McCullough A1, Previs SF2, Dasarathy J3, Lee K4, Osme A4, Kim C4, Ilchenko S4, Lorkowski SW5, Smith JD5, Dasarathy S1, Kasumov T6. Am J Physiol Endocrinol Metab. 2019 Sep 10. doi: 10.1152/ajpendo.00193.2019. [Epub ahead of print]
|
|
| |
|
|
| |
| 206. | Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study |
| |
Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
|
|
| |
|
|
| |
| 208. | Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis |
| |
Chen VL1,2, Wright AP1,3, Halligan B1, Chen Y1, Du X1, Handelman SK1,2, Long MT4, Kiel DP5,6, Speliotes EK1,2. Hepatol Commun. 2019 Jun 18;3(8):1073-1084. doi: 10.1002/hep4.1391. eCollection 2019 Aug.
|
|
| |
|
|
| |
| 210. | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life |
| |
Younossi ZM1,2, Stepanova M3, Lawitz EJ4, Reddy KR5, Wai-Sun Wong V6, Mangia A7, Muir AJ8, Jacobson I9, Djedjos CS10, Gaggar A10, Myers RP10, Younossi I3, Nader F3, Racila A3. Am J Gastroenterol. 2019 Aug 20. doi: 10.14309/ajg.0000000000000375. [Epub ahead of print]
|
|
| |
| 211. | Non-Alcoholic Fatty Liver Disease is Associated with Higher Metabolic Expenditure in Overweight and Obese Subjects: A Case-Control Study |
| |
Reddavide R1, Cisternino AM1, Inguaggiato R1, Rotolo O1, Zinzi I1, Veronese N1, Guerra V2, Fucilli F3, Di Giovanni G3, Leandro G4, Giannico S1, Caruso MG5. Nutrients. 2019 Aug 7;11(8). pii: E1830. doi: 10.3390/nu11081830.
|
|
| |
| 212. | Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation |
| |
Chen F1, Esmaili S1,2, Rogers G3, Bugianesi E4, Petta S5, Marchesini G6, Bayoumi A1, Metwally M1, Azardaryany MK1, Coulter S1, Choo JM3, Younes R4, Rosso C4, Liddle C1, Adams LA7, Craxì A5, George J1, Eslam M1. Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 219. | CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients |
| |
Pockros PJ1, Fuchs M2, Freilich B3, Schiff E4, Kohli A5, Lawitz EJ6, Hellstern PA7, Owens-Grillo J8, Van Biene C8, Shringarpure R8, MacConell L8, Shapiro D8, Cohen DE9. Liver Int. 2019 Aug 11. doi: 10.1111/liv.14209. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 224. | Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program |
| |
Huber Y1, Pfirrmann D2, Gebhardt I1, Labenz C1, Gehrke N1, Straub BK3, Ruckes C4, Bantel H5, Belda E6, Clément K7, Leeming DJ8, Karsdal MA8, Galle PR1, Simon P2, Schattenberg JM1. Aliment Pharmacol Ther. 2019 Jul 25. doi: 10.1111/apt.15427. [Epub ahead of print]
|
|
| |
| 225. | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial |
| |
Bril F1, Biernacki DM1, Kalavalapalli S1, Lomonaco R1, Subbarayan SK1, Lai J2, Tio F3, Suman A4, Orsak BK5, Hecht J6, Cusi K7,8. Diabetes Care. 2019 Aug;42(8):1481-1488. doi: 10.2337/dc19-0167. Epub 2019 May 21.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 231. | Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation? |
| |
Moris W1,2,3, Verhaegh P#2,3, Jonkers D2,3, Deursen CV1,2, Koek G2,3,4. Semin Liver Dis. 2019 Jul 22. doi: 10.1055/s-0039-1693114. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 235. | Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes |
| |
Barata L1, Feitosa MF1, Bielak LF2, Halligan B3, Baldridge AS4, Guo X5, Yerges-Armstrong LM6, Smith AV7, Yao J5, Palmer ND8, VanWagner LB4,9, Carr JJ10, Chen YI5, Allison M11, Budoff MJ12, Handelman SK3, Kardia SLR2, Mosley TH Jr13, Ryan K6, Harris TB14, Launer LJ14, Gudnason V15,16, Rotter JI5, Fornage M17, Rasmussen-Torvik LJ4, Borecki IB1, O'Connell JR6, Peyser PA2, Speliotes EK3, Province MA1. Hepatol Commun. 2019 Apr 18;3(7):894-907. doi: 10.1002/hep4.1353. eCollection 2019 Jul.
|
|
| |
|
|
| |
| 237. | Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease |
| |
Trout AT1,2,3, Hunte DE4, Mouzaki M5,6, Xanthakos SA5,6, Su W7, Zhang B5,8, Dillman JR4,9. Abdom Radiol (NY). 2019 Jul 16. doi: 10.1007/s00261-019-02123-y. [Epub ahead of print]
|
|
| |
| 238. | Clinically Significant Fibrosis is Associated With Longitudinal Increases in Fibrosis-4 and NAFLD Fibrosis Scores |
| |
Patel PJ1, Cheng JC2, Banh X2, Gracen L2, Radford-Smith D3, Hossain F4, Horsfall LU1, Lee Hayward K2, Williams S4, Johnson T4, Brown NN5, Saad N6, Stuart KA7, Russell AW8, Valery PC9, Clouston AD2, Irvine KM10, Bernard A11, Powell EE12. Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 243. | Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults |
| |
Lee SB#1,2, Kim MK#3, Kang S1,2, Park K1,2, Kim JH1,2, Baik SJ4, Nam JS1,2, Ahn CW1,2, Park JS1,5. Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186. doi: 10.3803/EnM.2019.34.2.179.
|
|
| |
|
|
| |
|
|
| |
| 246. | Epidemiology of chronic liver diseases in the USA in the past three decades |
| |
Younossi ZM1,2, Stepanova M3, Younossi Y3, Golabi P4,2, Mishra A4,2, Rafiq N4,2, Henry L3. Gut. 2019 Jul 31. pii: gutjnl-2019-318813. doi: 10.1136/gutjnl-2019-318813. [Epub ahead of print]
|
|
| |
|
|
| |
| 248. | Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B |
| |
Choi HSJ1,2, Brouwer WP3, Zanjir WMR1, de Man RA3, Feld JJ1, Hansen BE1,3,4, Janssen HLA1, Patel K1. Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 266. | Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease |
| |
Schwimmer JB1, Johnson JS2, Angeles JE3, Behling C4, Belt PH5, Borecki I6, Bross C7, Durelle J8, Goyal NP9, Hamilton G10, Holtz ML11, Lavine JE12, Mitreva M13, Newton KP14, Pan A15, Simpson PM16, Sirlin CB17, Sodergren E18, Tyagi R19, Yates KP20, Weinstock G21, Salzman NH22. Gastroenterology. 2019 Jun 27. pii: S0016-5085(19)41037-8. doi: 10.1053/j.gastro.2019.06.028. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 278. | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum |
| |
Cheung A1, Neuschwander-Tetri BA2, Kleiner DE3, Schabel E4, Rinella M5, Harrison S6, Ratziu V7, Sanyal AJ8, Loomba R9, Jeannin Megnien S10, Torstenson R11, Miller V12; Liver Forum Case Definitions Working Group. Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 286. | Non-Alcoholic Fatty Liver Disease, Liver Fibrosis Score and Cognitive Function in Middle-Aged Adults: The Framingham Study |
| |
Weinstein G1, Davis-Plourde K2,3, Himali JJ2,3,4, Zelber-Sagi S1,5, Beiser AS2,3,4, Seshadri S3,4,6. Liver Int. 2019 Jun 2. doi: 10.1111/liv.14161. [Epub ahead of print]
|
|
| |
| 287. | The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content |
| |
Gepner Y1, Shelef I2, Komy O3, Cohen N3, Schwarzfuchs D4, Bril N3, Rein M3, Serfaty D3, Kenigsbuch S3, Zelicha H3, Yaskolka Meir A3, Tene L3, Bilitzky A3, Tsaban G3, Chassidim Y2, Sarusy B5, Ceglarek U6, Thiery J6, Stumvoll M6, Blüher M6, Stampfer MJ7, Rudich A3, Shai I8. J Hepatol. 2019 May 8. pii: S0168-8278(19)30274-0. doi: 10.1016/j.jhep.2019.04.013. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 292. | Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study |
| |
De Silva NMG1,2,3, Borges MC1,2, Hingorani A4,5, Engmann J4, Shah T4, Zhang X6,7,8, Luan J6, Langenberg C6, Wong A9, Kuh D9, Chambers JC3,10,11, Zhang W12,13, Jarvelin MR12,14,15, Sebert S14, Auvinen J14,16; UCLEB consortium, Gaunt TR1,2, Lawlor DA17,2. Diabetes. 2019 May 14. pii: db181048. doi: 10.2337/db18-1048. [Epub ahead of print]
|
|
| |
| 293. | Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease |
| |
Gan D1, Wang L1, Jia M1, Ru Y1, Ma Y2, Zheng W3, Zhao X1, Yang F1, Wang T4, Mu Y5, Zhu S6. Clin Nutr. 2019 Apr 25. pii: S0261-5614(19)30199-2. doi: 10.1016/j.clnu.2019.04.023. [Epub ahead of print]
|
|
| |
| 294. | Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis |
| |
Mantovani A1, Lonardo A2, Vinco G1, Zoppini G1, Lippi G3, Bonora E1, Loomba R4, Tilg H5, Byrne CD6, Fabbri L7, Targher G8. Diabetes Metab. 2019 May 5. pii: S1262-3636(19)30068-0. doi: 10.1016/j.diabet.2019.04.008. [Epub ahead of print]
|
|
| |
|
|
| |
| 296. | Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta-Analysis |
| |
Zhou F1,2,3,4, Zhou J1,2,3, Wang W1,2,3, Zhang XJ1,2,3, Ji YX1,2,3, Zhang P1,2,3, She ZG1,2,3, Zhu L1,2,3, Cai J1,5,2, Li H1,2,3. Hepatology. 2019 May 9. doi: 10.1002/hep.30702. [Epub ahead of print]
|
|
| |
| 297. | Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study |
| |
Haldar D1, Kern B2, Hodson J3, James Armstrong M4, Adam R5, Berlakovich G6, Fritz J7, Feurstein B8, Popp W8, Karam V5, Muiesan P9, O'Grady J10, Jamieson N11, Wigmore SJ12, Pirenne J13, Ali Malek-Hosseini S14, Hidalgo E15, Tokat Y16, Paul A17, Pratschke J18, Bartels M19, Trunecka P20, Settmacher U21, Pinzani M22, Duvoux C23, Noel Newsome P24, Schneeberger S8; European Liver, Intestine Transplant Association (ELITA). J Hepatol. 2019 May 6. pii: S0168-8278(19)30272-7. doi: 10.1016/j.jhep.2019.04.011. [Epub ahead of print]
|
|
| |
| 298. | Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions! |
| |
Berger A1,2, Shili S3, Zuberbuhler F1,2, Hiriart JB3, Lannes A1,2, Chermak F3, Hunault G2, Foucher J3, Oberti F1,2, Fouchard-Hubert I1,2, Cales P1,2, de Ledinghen V3,4, Boursier J1,2. Clin Transl Gastroenterol. 2019 Apr;10(4):e00023. doi: 10.14309/ctg.0000000000000023.
|
|
| |
|
|
| |
| 300. | New sequential combinations of noninvasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD |
| |
Boursier J1, Guillaume M2, Leroy V3, Irlès M4, Roux M5, Lannes A6, Foucher J4, Zuberbuhler F6, Delabaudière C7, Barthelon J8, Michalak S9, Hiriart JB4, Peron JM2, Gerster T8, Le Bail B10, Riou J11, Hunault G5, Merrouche W4, Oberti F6, Pelade L8, Fouchard I6, Bureau C2, Calès P6, de Ledinghen V12. J Hepatol. 2019 May 15. pii: S0168-8278(19)30284-3. doi: 10.1016/j.jhep.2019.04.020. [Epub ahead of print]
|
|
| |
| 301. | Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts |
| |
Alexander M1, Loomis AK2, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6, Pasqua A7, Lapi F7, Rijnbeek P3, Mosseveld M3, Waterworth DM8, Kendrick S9, Sattar N10, Alazawi W11. BMC Med. 2019 May 20;17(1):95. doi: 10.1186/s12916-019-1321-x.
|
|
| |
|
|
| |
| 303. | Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014 |
| |
Kim D1, Cholankeril G1, Li AA2, Kim W3, Tighe SP1, Hameed B4, Kwo PY1, Harrison SA5, Younossi ZM6, Ahmed A1. Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 308. | Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial) |
| |
Ajmera VH1,2, Cachay E3, Ramers C4, Vodkin I2, Bassirian S1, Singh S1, Mangla N1, Bettencourt R1, Aldous JL5, Park D5, Lee D3, Blanchard J3, Mamidipalli A6, Boehringer A6, Aslam S7, Leinhard OD8,9, Richards L1, Sirlin C6, Loomba R1,2,10. Hepatology. 2019 Apr 23. doi: 10.1002/hep.30674. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 313. | Helicobacter pylori infection and NAFLD |
| |
Mantovani A1, Turino T1, Altomari A1, Lonardo A2, Zoppini G1, Valenti L3, Tilg H4, Byrne CD5, Targher G6. Metabolism. 2019 Apr 29. pii: S0026-0495(19)30084-8. doi: 10.1016/j.metabol.2019.04.012. [Epub ahead of print]
|
|
| |
| 314. | Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution |
| |
Alferink LJM1, Trajanoska K2,3, Erler NS4, Schoufour JD2,3, de Knegt RJ1, Ikram MA2, Janssen HLA1,5, Franco OH2,6, Metselaar HJ1, Rivadeneira F2,3, Darwish Murad S1. J Bone Miner Res. 2019 May 10. doi: 10.1002/jbmr.3713. [Epub ahead of print]
|
|
| |
| 315. | Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis |
| |
Vitaglione P1,2, Mazzone G3, Lembo V3, D'Argenio G3, Rossi A3, Guido M4, Savoia M5, Salomone F6, Mennella I1, De Filippis F1,2, Ercolini D1,2, Caporaso N2,3, Morisco F2,3. J Nutr Sci. 2019 Apr 22;8:e15. doi: 10.1017/jns.2019.10. eCollection 2019.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 325. | Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department |
| |
Likhitsup A1,2, Dundulis J1, Ansari S3, El-Halawany H1, Michelson R1, Hutton C4, Kennedy K5, Helzberg JH1,2, Chhabra R1,2. Ann Gastroenterol. 2019 May-Jun;32(3):283-286. doi: 10.20524/aog.2019.0371. Epub 2019 Mar 15.
|
|
| |
|
|
| |
| 327. | A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease |
| |
Ma J1,2, Nano J3,4,5, Ding J6, Zheng Y7, Hennein R1, Liu C1,8, Speliotes EK9, Huan T1, Song C1,10, Mendelson MM1,11, Joehanes R1, Long MT12, Liang L13,14, Smith JA15, Reynolds LM6, Ghanbari M3,16, Muka T3, van Meurs JBJ3,17, Alferink LJM18, Franco OH3, Dehghan A3,19, Ratliff S15, Zhao W15, Bielak L15, Kardia SLR15, Peyser PA15, Ning H7, VanWagner LB7,20, Lloyd-Jones DM7, Carr JJ21, Greenland P7, Lichtenstein AH22, Hu FB23, Liu Y6, Hou L7, Darwish Murad S18, Levy D24. Diabetes. 2019 May;68(5):1073-1083. doi: 10.2337/DB18-1193. Epub 2019 Apr 1.
|
|
| |
|
|
| |
|
|
| |
| 330. | A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease |
| |
Caussy C1,2, Tripathi A3,4,5,6, Humphrey G4, Bassirian S1, Singh S1, Faulkner C1, Bettencourt R1,7, Rizo E1, Richards L1, Xu ZZ4, Downes MR8, Evans RM8, Brenner DA1,9, Sirlin CB10, Knight R3,4,11,12, Loomba R13,14,15. Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 334. | The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials |
| |
Sanyal AJ1, Harrison SA2, Ratziu V3, Abdelmalek MF4, Diehl AM4, Caldwell S5, Shiffman ML6, Schall RA7, Jia C7, McColgan B7, Djedjos CS7, McHutchison JG7, Subramanian GM7, Myers RP7, Younossi Z8, Muir AJ4, Afdhal NH9, Bosch J10,11, Goodman Z8. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 343. | Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule |
| |
Yabut JM1,2, Crane JD3, Green AE1,2, Keating DJ4, Khan WI2,5,6, Steinberg GR1,2,6,7. Endocr Rev. 2019 Mar 22. pii: er.2018-00283. doi: 10.1210/er.2018-00283. [Epub ahead of print]
|
|
| |
| 344. | Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease |
| |
Srivastava A1, Gailer R1, Tanwar S1, Trembling P1, Parkes J2, Rodger A3, Suri D4, Thorburn D1, Sennett K5, Morgan S6, Tsochatzis EA7, Rosenberg W8. J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30227-2. doi: 10.1016/j.jhep.2019.03.033. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 351. | Obesity in the critically ill: a narrative review |
| |
Schetz M1, De Jong A2, Deane AM3,4, Druml W5, Hemelaar P6, Pelosi P7,8, Pickkers P6,9, Reintam-Blaser A10,11, Roberts J12,13,14,15, Sakr Y16, Jaber S2.
Intensive Care Med. 2019 Mar 19. doi: 10.1007/s00134-019-05594-1. [Epub ahead of print]
|
|
| |
|
|
| |
| 353. | Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography |
| |
Yin Z1, Murphy MC1, Li J1, Glaser KJ1, Mauer AS2, Mounajjed T3, Therneau TM4, Liu H4, Malhi H2, Manduca A1,5, Ehman RL1, Yin M6. Eur Radiol. 2019 Mar 18. doi: 10.1007/s00330-019-06076-0. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 357. | Sarcopenic obesity in fatty liver |
| |
Merli M1, Lattanzi B, Aprile F. JCurr Opin Clin Nutr Metab Care. 2019 Mar 18. doi: 10.1097/MCO.0000000000000558. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 362. | Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis |
| |
Klebanoff MJ1, Corey KE2,3, Samur S4,5, Choi JG5, Kaplan LM2,3, Chhatwal J2,3,5, Hur C6. JAMA Netw Open. 2019 Feb 1;2(2):e190047. doi: 10.1001/jamanetworkopen.2019.0047.
|
|
| |
| 363. | Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume |
| |
Abeles RD1, Mullish BH1, Forlano R1, Kimhofer T2, Adler M1, Tzallas A3, Giannakeas N3, Yee M4, Mayet J5, Goldin RD6, Thursz MR1, Manousou P1. Aliment Pharmacol Ther. 2019 Mar 5. doi: 10.1111/apt.15192. [Epub ahead of print]
|
|
| |
| 364. | An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease(NAFLD) associated with obesity |
| |
Nistal E1, Sáenz de Miera LE2, Ballesteros Pomar M3, Sánchez Campos S2, García Mediavilla MV2, Álvarez Cuenllas B4, Linares P5, Olcoz JL3, Arias Loste MT6, García Lobo JM7, Crespo J8, González Gallego J2, Jorquera Plaza F9. Rev Esp Enferm Dig. 2019 Feb 27;111. doi: 10.17235/reed.2019.6068/2018. [Epub ahead of print]
|
|
| |
| 365. | Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease(NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study |
| |
Vilar-Gomez E1, Athinarayanan SJ2, Adams RN2, Hallberg SJ2,3, Bhanpuri NH2, McKenzie AL2, Campbell WW4, McCarter JP2,5, Phinney SD2, Volek JS2,6, Chalasani N1. BMJ Open. 2019 Feb 25;9(2):e023597. doi: 10.1136/bmjopen-2018-023597.
|
|
| |
|
|
| |
|
|
| |
| 368. | Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis |
| |
Regev A1, Palmer M2, Avigan MI3, Dimick-Santos L3, Treem WR4, Marcinak JF5, Seekins D6, Krishna G7, Anania FA3, Freston JW8, Lewis JH9, Sanyal AJ10, Chalasani N1. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 374. | NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis |
| |
Harrison SA1,2, Rossi SJ3, Paredes AH4, Trotter JF5, Bashir MR6, Guy CD7, Banerjee R8, Jaros MJ9, Owers S2, Baxter BA3, Ling L3, DePaoli AM3. Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 377. | Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial |
| |
Parker HM1,2, Cohn JS3, O'Connor HT4,5, Garg ML6, Caterson ID7, George J8, Johnson NA9,10,11. Nutrients. 2019 Feb 23;11(2). pii: E475. doi: 10.3390/nu11020475.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 382. | Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study |
| |
Ren XY1,2, Shi D1,2, Ding J3, Cheng ZY2,4, Li HY3, Li JS2, Pu HQ3, Yang AM2,5, He CL2, Zhang JP2, Ma YB2, Zhang YW4, Zheng TZ5, Bai YN6, Cheng N7. Lipids Health Dis. 2019 Feb 11;18(1):47. doi: 10.1186/s12944-019-0984-9.
|
|
| |
|
|
| |
|
|
| |
| 385. | Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis |
| |
Younossi ZM1, Stepanova M2, Anstee QM3, Lawitz EJ4, Wong VW5, Romero-Gomez M6, Kersey K7, Li G7, Subramanian GM7, Myers RP7, Djedjos CS7, Okanoue T8, Trauner M9, Goodman Z10, Harrison SA11. Clin Gastroenterol Hepatol. 2019 Feb 16. pii: S1542-3565(19)30187-9. doi: 10.1016/j.cgh.2019.02.024. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 389. | Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease |
| |
Eddowes PJ1, Sasso M2, Allison M3, Tsochatzis E4, Anstee QM5, Sheridan D6, Guha IN7, Cobbold JF8, Deeks JJ9, Paradis V10, Bedossa P10, Newsome PN11. Gastroenterology. 2019 Jan 25. pii: S0016-5085(19)30105-2. doi: 10.1053/j.gastro.2019.01.042. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 396. | Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States |
| |
Shapiro WL1,2,3, Yu EL1,3, Arin JC1, Murray KF4, Ali S5, Desai NK6, Xanthakos SA7,8, Lin HC9, Alkhouri N10,11, Abdou R12, Abrams SH13,14,15,16, Butler MW17, Faasse SA18,19, Gillis LA20, Hadley TA18, Jain AK21, Kavan M22, Kordy K23, Lee P24, Panganiban J25, Pohl JF22, Potter C26, Rudolph B27, Sundaram SS28,29, Joshi S1,30, Proudfoot JA31, Goyal NP1,3, Harlow KE1,3, Newton KP1,3, Schwimmer JB1,3. J Pediatr Gastroenterol Nutr. 2019 Feb;68(2):182-189. doi: 10.1097/MPG.0000000000002194. |
|
| |
| 397. | Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial |
| |
Schwimmer JB1,2, Ugalde-Nicalo P1, Welsh JA3,4,5, Angeles JE1, Cordero M3, Harlow KE1,2, Alazraki A6, Durelle J1, Knight-Scott J6, Newton KP1,2, Cleeton R3, Knott C7, Konomi J3, Middleton MS8, Travers C9, Sirlin CB8, Hernandez A3, Sekkarie A5, McCracken C4,9, Vos MB3,4,5. JAMA. 2019 Jan 22;321(3):256-265. doi: 10.1001/jama.2018.20579. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 403. | Prevalence and Risk Factors if Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis |
| |
Pelusi S1, Cespiati A2, Rametta R3, Pennisi G4, Mannisto V5, Rosso C6, Baselli G1, Dongiovanni P3, Fracanzani AL2, Badiali S7, Maggioni M8, Craxi A4, Fargion S2, Prati D9, Nobili V10, Bugianesi E6, Romeo S11, Pihlajamaki J5, Petta S4, Valenti L12. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30074-6. doi: 10.1016/j.cgh.2019.01.027. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 407. | Perinatal Nutritional Reprogramming of the Epigenome Promotes Subsequent Development of Nonalcoholic Steatohepatitis |
| |
Gutierrez Sanchez LH1, Tomita K2, Guo Q2, Furuta K2, Alhuwaish H2, Hirsova P2,3, Baheti S4, Alver B5, Hlady R5, Robertson KD5, Ibrahim SH1,2. Hepatol Commun. 2018 Oct 1;2(12):1493-1512. doi: 10.1002/hep4.1265. eCollection 2018 Dec. |
|
| |
| 408. | Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients |
| |
Uehara D1,2, Seki Y3, Kakizaki S4, Horiguchi N2, Tojima H2, Yamazaki Y2, Sato K2, Yamada M1,5, Uraoka T2, Kasama K3. Obes Surg. 2018 Dec 12. doi: 10.1007/s11695-018-03641-2. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 416. | NASH in Lean Individuals |
| |
Younes R1, Bugianesi E1. Semin Liver Dis. 2019 Jan 17. doi: 10.1055/s-0038-1677517. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 420. | Predictors of De NovoNonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis |
| |
Galvin Z1,2, Rajakumar R1, Chen E1, Adeyi O1,2, Selzner M1,3, Grant D1,3, Sapisochin G1,3, Greig P1,3, Cattral M1,3, McGilvray I1,3, Ghanekar A1,3, Selzner N1,2, Lilly L1,2, Patel K1,2, Bhat M1,2. Liver Transpl. 2019 Jan;25(1):56-67. doi: 10.1002/lt.25338. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 426. | Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies |
| |
Prat LI1,2, Roccarina D1, Lever R3, Lombardi R1, Rodger A3,4, Hall A1,5, Luong TV1, Bhagani S3, Tsochatzis E1. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001942. [Epub ahead of print] |
|
| |
| 427. | Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study |
| |
Lemoine M1, Assoumou L2, De Wit S3, Girard PM4, Valantin MA5, Katlama C5, Necsoi C3, Campa P4, Huefner AD6, Schulze Zur Wiesch J6, Rougier H4, Bastard JP7,8, Stocker H9, Mauss S10, Serfaty L11, Ratziu V12, Menu Y13, Schlue J14, Behrens G15, Bedossa P16, Capeau J8, Ingiliz P17, Costagliola D2. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001936. [Epub ahead of print] |
|
| |
| 428. | Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity |
| |
Yu EL1, Golshan S2, Harlow KE1, Angeles JE3, Durelle J3, Goyal NP1, Newton KP1, Sawh MC1, Hooker J4, Sy EZ4, Middleton MS4, Sirlin CB4, Schwimmer JB5. J Pediatr. 2018 Dec 14. pii: S0022-3476(18)31609-3. doi: 10.1016/j.jpeds.2018.11.021. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 431. | Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand |
| |
Calzadilla-Bertot L1, Jeffrey GP1,2, Jacques B2, McCaughan G3, Crawford M3, Angus P4, Jones R4, Gane E5, Munn S5, Macdonald G6, Fawcett J6, Wigg A7, Chen J7, Fink M8, Adams LA1,2. Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361. |
|
| |
|
|
| |
|
|
| |
| 434. | Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease |
| |
Alfani R1,2, Vassallo E3,4, De Anseris AG5, Nazzaro L6, D'Acunzo I7,8, Porfito C9,10, Mandato C11, Vajro P12,13,14,15. Children (Basel). 2018 Dec 13;5(12). pii: E169. doi: 10.3390/children5120169. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 439. | Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK |
| |
Williams R1, Alexander G2, Aspinall R3, Batterham R4, Bhala N5, Bosanquet N6, Severi K7, Burton A8, Burton R9, Cramp ME10, Day N11, Dhawan A12, Dillon J13, Drummond C14, Dyson J15, Ferguson J16, Foster GR17, Gilmore I18, Greenberg J19, Henn C9, Hudson M15, Jarvis H20, Kelly D21, Mann J22, McDougall N23, McKee M24, Moriarty K25, Morling J26, Newsome P27, O'Grady J12, Rolfe L9, Rice P28, Rutter H29, Sheron N30, Thorburn D31, Verne J9, Vohra J32, Wass J33, Yeoman A34. Lancet. 2018 Dec 1;392(10162):2398-2412. doi: 10.1016/S0140-6736(18)32561-3. Epub 2018 Nov 22. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 451. | Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease |
| |
Younossi ZM1, Stepanova M2, Ong J3, Yilmaz Y4, Duseja A5, Eguchi Y6, El Kassas M7, Castellanos-Fernandez M8, George J9, Jacobson IM10, Bugianesi E11, Wai-Sun Wong V12, Arrese M13, de Ledinghen V14, Romero-Gomez M15, Mendez-Sanchez N16, Ahmed A17, Wong R18, Papatheodoridis G19, Serfaty L20, Younossi I2, Nader F2, Ziayee M2, Afendy A2; Global NASH Council. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31276-X. doi: 10.1016/j.cgh.2018.11.033. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 462. | European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale |
| |
Mann JP1, Vreugdenhil A2, Socha P3, Ja?czyk W3, Baumann U4, Rajwal S5, Casswall T6, Marcus C7, van Mourik I8, O'Rahilly S9, Savage DB9, Noble-Jamieson G10, Lacaille F11, Dabbas M11, Dubern B12, Kelly DA8, Nobili V13, Anstee QM14. Contemp Clin Trials. 2018 Dec;75:67-71. doi: 10.1016/j.cct.2018.11.003. Epub 2018 Nov 5. |
|
| |
|
|
| |
| 464. | Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease |
| |
Glass O1, Henao R2,3, Patel K4, Guy CD5, Gruss HJ6, Syn WK7,8, Moylan CA9, Streilein R10, Hall R10, Mae Diehl A9, Abdelmalek MF9. Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov. |
|
| |
| 465. | Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design |
| |
Rudolph B1, Bjorklund N2, Ovchinsky N3, Kogan-Liberman D3, Perez A3, Liszewski M4, Levin TL4, Ewart M4, Liu Q4, Xue X5, Viswanathan S5, Strickler HD5. Contemp Clin Trials. 2018 Dec;75:51-58. doi: 10.1016/j.cct.2018.10.012. Epub 2018 Oct 27. |
|
| |
|
|
| |
|
|
| |
| 468. | Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC |
| |
Grohmann M1, Wiede F2, Dodd GT1, Gurzov EN3, Ooi GJ4, Butt T1, Rasmiena AA5, Kaur S1, Gulati T5, Goh PK2, Treloar AE5, Archer S6, Brown WA4, Muller M7, Watt MJ3, Ohara O8, McLean CA9, Tiganis T10. Cell. 2018 Nov 15;175(5):1289-1306.e20. doi: 10.1016/j.cell.2018.09.053. Epub 2018 Oct 25. |
|
| |
|
|
| |
|
|
| |
| 471. | Validation of Serum Test for Advanced Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis |
| |
Loomba R1, Jain A2, Diehl AM3, Guy CD4, Portenier D5, Sudan R5, Singh S6, Faulkner C6, Richards L6, Hester KD2, Okada L2, Li XJ2, Mimms L2, Abdelmalek MF7. Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31247-3. doi: 10.1016/j.cgh.2018.11.004. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 479. | Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH |
| |
Chalasani N1, Abdelmalek MF2, Loomba R3, Kowdley KV4, McCullough AJ5, Dasarathy S5, Neuschwander-Tetri BA6, Terrault N7, Ferguson B, Shringarpure R8, Shapiro D8, Sanyal AJ9. Liver Int. 2018 Sep 25. doi: 10.1111/liv.13974. [Epub ahead of print] |
|
| |
|
|
| |
| 481. | Longitudinal analysis of risk of Non-Alcoholic Fatty Liver Disease (NAFLD) in adulthood |
| |
Cuthbertson DJ1, Brown E1, Koskinen J2,3, Magnussen CG2,4, Hutri-Kähönen N5, Sabin M6,7, Tossavainen P8, Jokinen E9, Laitinen T10, Viikari J11,12, Raitakari OT2, Juonala M6,11,12. Liver Int. 2018 Oct 22. doi: 10.1111/liv.13993. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 489. | Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease |
| |
Munteanu M1,2,3, Pais R2,3, Peta V1, Deckmyn O1, Moussalli J2, Ngo Y1, Rudler M2, Lebray P2, Charlotte F2, Thibault V2, Lucidarme O2,3, Ngo A2,3, Imbert-Bismut F2, Housset C3, Thabut D2,3, Ratziu V2,3, Poynard T2,3; FibroFrance Group. Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 502. | Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study |
| |
Ooi GJ1,2, Burton PR3,4, Bayliss J5,6, Raajendiran A5,6, Earnest A7, Laurie C3,4, Kemp WW8, McLean CA9, Roberts SK8, Watt MJ5,6, Brown WA3,4. Obes Surg. 2018 Sep 18. doi: 10.1007/s11695-018-3479-2. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 507. | Factors Associated with Histologic Response in Adult Patients with Nonalcoholic Steatohepatitis |
| |
Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2018 Sep 14. pii: S0016-5085(18)34977-1. doi: 10.1053/j.gastro.2018.09.021. [Epub ahead of print] |
|
| |
| 508. | An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease |
| |
Younossi ZM1,2,3, Karrar A4,5, Pierobon M6, Birerdinc A4, Stepanova M4,5, Abdelatif D4,7, Younoszai Z5, Jeffers T5, Felix S5, Jeiran K6, Hodge A6, Zhou W6, Monge F4,7, Alaparthi L4,7, Chandhoke V5,6, Goodman ZD4,7, Petricoin EF6. BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 512. | Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial |
| |
Harrison SA1, Dennis A2, Fiore MM2, Kelly MD2, Kelly CJ2, Paredes AH3, Whitehead JM3, Neubauer S1,2, Traber PG4, Banerjee R2. PLoS One. 2018 Sep 7;13(9):e0203054. doi: 10.1371/journal.pone.0203054. eCollection 2018. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 517. | Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis |
| |
Hooker JC1, Hamilton G1, Park CC1, Liao S1, Wolfson T2, Dehkordy SF1, Hong CW1, Mamidipalli A1, Gamst A2, Loomba R3, Sirlin CB4. Abdom Radiol (NY). 2018 Aug 20. doi: 10.1007/s00261-018-1745-3. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 521. | Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models |
| |
Green CJ1, Parry SA1, Gunn PJ1, Ceresa CDL1,2, Rosqvist F1,3, Piché ME1,4, Hodson L5. Horm Mol Biol Clin Investig. 2018 Aug 11. pii: /j/hmbci.ahead-of-print/hmbci-2018-0038/hmbci-2018-0038.xml. doi: 10.1515/hmbci-2018-0038. [Epub ahead of print] |
|
| |
|
|
| |
| 523. | Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease |
| |
Alexander M1, Loomis AK2, Fairburn-Beech J1, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6, Pasqua A7, Lapi F7, Rijnbeek P3, Mosseveld M3, Avillach P8, Egger P1, Kendrick S1, Waterworth DM1, Sattar N9, Alazawi W10. BMC Med. 2018 Aug 13;16(1):130. doi: 10.1186/s12916-018-1103-x. |
|
| |
| 524. | Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis |
| |
Younossi Z1,2, Tacke F3, Arrese M4,5, Sharma BC6, Mostafa I7, Bugianesi E8, Wong VW9, Yilmaz Y10, George J11, Fan J12, Vos MB13. Hepatology. 2018 Sep 4. doi: 10.1002/hep.30251. [Epub ahead of print] |
|
| |
| 525. | The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options |
| |
Younossi Z1, Stepanova M2, Sanyal AJ3, Harrison SA4, Ratziu V5, Abdelmalek MF6, Diehl AM6, Caldwell S7, Shiffman ML8, Schall RA9, McColgan B9, Mani Subramanian G9, Myers RP9, Muir A6, Afdhal NH10, Bosch J11, Goodman Z2. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295-5. doi: 10.1016/j.jhep.2018.08.013. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 528. | GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease |
| |
Loomba R1, Kayali Z2, Noureddin M3, Ruane P4, Lawitz EJ5, Bennett M6, Wang L7, Harting E7, Tarrant JM7, McColgan BJ7, Chung C7, Ray AS7, Subramanian GM7, Myers RP7, Middleton MS8, Lai M9, Charlton M10, Harrison SA11. Gastroenterology. 2018 Jul 27. pii: S0016-5085(18)34815-7. doi: 10.1053/j.gastro.2018.07.027. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 536. | Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts |
| |
Mayo R1, Crespo J2, Martínez-Arranz I1, Banales JM3, Arias M2, Mincholé I1, Aller de la Fuente R4, Jimenez-Agüero R3, Alonso C1, de Luis DA5, Vitek L6, Stritesky J6, Caballería J7, Romero-Gómez M8, Martín-Duce A9, Mugüerza Huguet JM10, Busteros-Moraza JI11, Idowu MO12, Castro A1, Martínez-Chantar ML13, Ortiz P1, Bruha R6, Lu SC14, Bedossa P15, Noureddin M14, Sanyal AJ16, Mato JM13. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 541. | Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis |
| |
Harrison SA1, Abdelmalek MF2, Caldwell S3, Shiffman ML4, Diehl AM2, Ghalib R5, Lawitz EJ6, Rockey DC7, Schall RA8, Jia C8, McColgan BJ8, McHutchison JG8, Subramanian GM8, Myers RP8, Younossi Z9, Ratziu V10, Muir AJ2, Afdhal NH11, Goodman Z9, Bosch J12, Sanyal AJ13; GS-US-321-0105GS-US-321-0106 Investigators. Gastroenterology. 2018 Jul 7. pii: S0016-5085(18)34758-9. doi: 10.1053/j.gastro.2018.07.006. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 547. | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study |
| |
Eriksson JW1, Lundkvist P2, Jansson PA3, Johansson L4, Kvarnström M5, Moris L6, Miliotis T5, Forsberg GB5, Risérus U7, Lind L2, Oscarsson J5. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3. |
|
| |
| 548. | Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis |
| |
Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 551. | Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies |
| |
Snyder HS1,2, Sakaan SA1,2, March KL1,2, Siddique O3, Cholankeril R4, Cummings CD1,2, Gadiparthi C5, Satapathy SK5, Ahmed A6, Cholankeril G5,6. J Clin Transl Hepatol. 2018 Jun 28;6(2):168-174. doi: 10.14218/JCTH.2017.00050. Epub 2018 Mar 25. |
|
| |
|
|
| |
| 553. | A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis |
| |
Awosika O1,2,3,4, Eleryan MG1,2,3,4, Rengifo-Pardo M1,2,3,4, Doherty L1,2,3,4, Martin LW1,2,3,4, Ehrlich A1,2,3,4. J Clin Aesthet Dermatol. 2018 Jun;11(6):33-37. Epub 2018 Jun 1. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 557. | Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates |
| |
Younossi Z1, Stepanova M2, Ong JP3, Jacobson IM4, Bugianesi E5, Duseja A6, Eguchi Y7, Wong VW8, Negro F9, Yilmaz Y10, Romero-Gomez M11, George J12, Ahmed A13, Wong R14, Younossi I2, Ziayee M2, Afendy A2; Global NASH Council.. Clin Gastroenterol Hepatol. 2018 Jun 13. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print] |
|
| |
| 558. | Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-stage Liver Disease Scores Compared With Placebo |
| |
Frenette CT1, Morelli G2, Shiffman ML3, Frederick RT4, Rubin RA5, Fallon MB6, Cheng JT7, Cave M8, Khaderi SA9, Massoud O10, Pyrsopoulos N11, Park JS12, Robinson JM13, Yamashita M13, Spada AP13, Chan JL13, Hagerty DT13. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30622-0. doi: 10.1016/j.cgh.2018.06.012. [Epub ahead of print] |
|
| |
| 559. | Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption |
| |
Sanders FWB1, Acharjee A1,2, Walker C1, Marney L1, Roberts LD1,2,3, Imamura F4, Jenkins B1, Case J2, Ray S1,5, Virtue S6, Vidal-Puig A6, Kuh D7, Hardy R7, Allison M8, Forouhi N4, Murray AJ9, Wareham N4, Vacca M1,2,5,6, Koulman A1, Griffin JL10,1Genome Biol. 2018 Jun 20;19(1):79. doi: 10.1186/s13059-018-1439-8. 1. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 563. | Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial |
| |
Bomhof MR1,2, Parnell JA3, Ramay HR4, Crotty P5, Rioux KP5,6, Probert CS7, Jayakumar S5, Raman M5, Reimer RA8,9. Eur J Nutr. 2018 May 19. doi: 10.1007/s00394-018-1721-2. [Epub ahead of print] |
|
| |
| 564. | Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis |
| |
Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 568. | Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease |
| |
Mitchell T1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Ching H2, Hamdorf J2, Adams LA4,5. Am J Gastroenterol. 2018 Jun 14. doi: 10.1038/s41395-018-0133-5. [Epub ahead of print] |
|
| |
| 569. | NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances |
| |
Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5. Am J Gastroenterol. 2018 Jun 8. doi: 10.1038/s41395-018-0088-6. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 573. | Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease |
| |
Britton L1,2,3,4, Bridle K1,2, Reiling J1,2,5, Santrampurwala N1,2,4, Wockner L4, Ching H6, Stuart K1,3, Subramaniam VN4,7, Jeffrey G6,8, St Pierre T9, House M9, Gummer J10, Trengove R10, Olynyk J11,12, Crawford D1,2, Adams L6,8. Hepatol Commun. 2018 Apr 27;2(6):644-653. doi: 10.1002/hep4.1190. eCollection 2018 Jun. |
|
| |
|
|
| |
| 575. | The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease |
| |
Lewis JE1, Atlas SE1, Higuera OL1, Fiallo A1, Rasul A1, Farooqi A1, Kromo O2, Lantigua LA1, Tiozzo E1, Woolger JM3, Goldberg S4, Mendez A3, Rodriguez AE3, Konefal J5. Evid Based Complement Alternat Med. 2018 May 3;2018:1751583. doi: 10.1155/2018/1751583. eCollection 2018. |
|
| |
|
|
| |
| 577. | Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration |
| |
Patel YA1, Gifford EJ2, Glass LM3,4, Turner MJ5, Han B5, Moylan CA6, Choi S6, Suzuki A6, Provenzale D6,5, Hunt CM6,5. Dig Dis Sci. 2018 May 19. doi: 10.1007/s10620-018-5123-3. [Epub ahead of print] |
|
| |
| 578. | Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis |
| |
Petta S1, Sebastiani G2, Bugianesi E3, Viganò M4, Wong VW5, Berzigotti A6, Fracanzani AL7, Anstee QM8, Marra F9, Barbara M10, Calvaruso V10, Cammà C10, Di Marco V10, Craxì A10, de Ledinghen V11. J Hepatol. 2018 May 23. pii: S0168-8278(18)32065-8. doi: 10.1016/j.jhep.2018.05.019. [Epub ahead of print] |
|
| |
|
|
| |
| 580. | Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data |
| |
Arsik I1, Frediani JK2, Frezza D3, Chen W4, Ayer T5, Keskinocak P6, Jin R7, Konomi JV8, Barlow SE9, Xanthakos SA10, Lavine JE11, Vos MB12. Children (Basel). 2018 May 25;5(6). pii: E64. doi: 10.3390/children5060064. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 586. | Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 |
| |
Estes C1, Anstee QM2, Arias-Loste MT3, Bantel H4, Bellentani S5, Caballeria J6, Colombo M7, Craxi A8, Crespo J9, Day CP2, Geier A10, Kondili LA11, Lazarus JV12, Loomba R13, Manns MP4, Marchesini G14, Negro F15, Petta S16, Ratziu V17, Romero-Gomez M18, Sanyal A19, Schattenberg JM20, Tacke F21, Trautwein C22, Wei L23, Zeuzem S24, Razavi H25. J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32121-4. doi: 10.1016/j.jhep.2018.05.036. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 590. | Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure |
| |
Valbusa F1, Agnoletti D1, Scala L1, Grillo C1, Arduini P2, Bonapace S3, Calabria S1, Scaturro G1, Mantovani A4, Zoppini G4, Turcato E2, Maggioni AP5, Arcaro G1, Targher G6. Int J Cardiol. 2018 May 2. pii: S0167-5273(18)30544-8. doi: 10.1016/j.ijcard.2018.04.129. [Epub ahead of print] |
|
| |
| 591. | US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease |
| |
Hudert CA1, Tzschätzsch H1, Guo J1, Rudolph B1, Bläker H1, Loddenkemper C1, Luck W1, Müller HP1, Baumgart DC1, Hamm B1, Braun J1, Holzhütter HG1, Wiegand S1, Sack I1. Radiology. 2018 May 15:172928. doi: 10.1148/radiol.2018172928. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 596. | Liver fat imaging - a clinical overview of ultrasound, CT, and MR imaging |
| |
Zhang Y1, Fowler KJ2, Hamilton G1, Cui J1, Sy EZ1, Balanay M1, Hooker JC1, Szeverenyi NM1, Sirlin CB1. Br J Radiol. 2018 May 3:20170959. doi: 10.1259/bjr.20170959. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 600. | Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings from a Multi-ethnic Cohort |
| |
Tricò D1,2, Caprio S3, Umano GR3,4, Pierpont B3, Nouws J3, Galderisi A3, Kim G5, Mata MM3, Santoro N3. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30035. [Epub ahead of print] |
|
| |
|
|
| |
| 602. | Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis |
| |
Lawitz EJ1, Coste A2, Poordad F2, Alkhouri N2, Loo N2, McColgan BJ3, Tarrant JM3, Nguyen T3, Han L3, Chung C3, Ray AS3, McHutchison JG3, Subramanian GM3, Myers RP3, Middleton MS4, Sirlin C4, Loomba R4, Nyangau E5, Fitch M5, Li K5, Hellerstein M5. Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30404-X. doi: 10.1016/j.cgh.2018.04.042. [Epub ahead of print] |
|
| |
|
|
| |
| 604. | Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors |
| |
Mariabeatrice P1, Andrea I1, Giuseppe L1, Michela M1, Endrit S1, Francesca A1, Rizzi SF1, La Fortezza RF1, Rosa L1, Antonella C1, Michele B1, Gioacchino L2, Enzo I1, Alfredo DL1. Inflamm Bowel Dis. 2018 Apr 23. doi: 10.1093/ibd/izy051. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 607. | Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH |
| |
Boursier J1, Anty R2, Vonghia L3, Moal V1, Vanwolleghem T3, Canivet CM2, Michalak S1, Bonnafous S2, Michielsen P3, Oberti F1, Iannelli A2, Van Gaal L3, Patouraux S2, Blanchet O1, Verrijken A3, Gual P2, Rousselet MC1, Driessen A3, Hunault G1, Bertrais S1, Tran A2, Calès P1, Francque S3. Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25. |
|
| |
| 608. | Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease |
| |
Harlow KE1, Africa JA1, Wells A2, Belt PH3, Behling CA4, Jain AK5, Molleston JP6, Newton KP1, Rosenthal P7, Vos MB8, Xanthakos SA9, Lavine JE10, Schwimmer JB11; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). J Pediatr. 2018 Apr 13. pii: S0022-3476(18)30281-6. doi: 10.1016/j.jpeds.2018.02.038. [Epub ahead of print] |
|
| |
|
|
| |
| 610. | Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD |
| |
Caussy C1,2, Hsu C1, Lo MT3, Liu A1, Bettencourt R1, Ajmera VH1, Bassirian S1, Hooker J4, Sy E4, Richards L1, Schork N5, Schnabl B1,6, Brenner DA1,6, Sirlin CB4, Chen CH3, Loomba R1,6,7; Genetics of NAFLD in Twins Consortium. Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 623. | Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease |
| |
Grove JI1,2, Thiagarajan P1,2, Astbury S1,2, Harris R1,2, Delahooke T3, Guha IN1,2, Aithal GP1,2. Liver Int. 2018 Mar 1. doi: 10.1111/liv.13733. [Epub ahead of print] |
|
| |
|
|
| |
| 625. | Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease |
| |
Bertot LC1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Chin J2, Huang Y1, Adams LA1,2. Liver Int. 2018 Mar 25. doi: 10.1111/liv.13739. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 631. | Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic FattyLiver Disease in Patients with Type 2 Diabetes Mellitus |
| |
Bril F1,2, Millán L3, Kalavalpalli S1, McPhaul MJ4, Caulfield MP4, Martinez-Arranz I3, Alonso C3, Ortiz Betes P3, Mato JM5, Cusi K1,2. Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285. [Epub ahead of print] |
|
| |
| 632. | Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort |
| |
Alexander KS1, Zakai NA1,2, Lidofsky SD1, Callas PW3, Judd SE4, Tracy RP2,5, Cushman M1,2. PLoS One. 2018 Mar 12;13(3):e0194153. doi: 10.1371/journal.pone.0194153. eCollection 2018. |
|
| |
| 633. | Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research |
| |
Mancini M1, Summers P2, Faita F3, Brunetto MR4, Callea F5, De Nicola A6, Di Lascio N3, Farinati F7, Gastaldelli A8, Gridelli B9, Mirabelli P10, Neri E11, Salvadori PA3, Rebelos E4, Tiribelli C12, Valenti L13, Salvatore M10, Bonino F1. World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 640. | NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| |
Harrison SA1, Rinella ME2, Abdelmalek MF3, Trotter JF4, Paredes AH5, Arnold HL6, Kugelmas M7, Bashir MR8, Jaros MJ9, Ling L10, Rossi SJ10, DePaoli AM10, Loomba R11. Lancet. 2018 Mar 5. pii: S0140-6736(18)30474-4. doi: 10.1016/S0140-6736(18)30474-4. [Epub ahead of print] |
|
| |
| 641. | De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients |
| |
Gitto S1, de Maria N1, di Benedetto F2, Tarantino G2, Serra V2, Maroni L3, Cescon M3, Pinna AD3, Schepis F1, Andreone P4, Villa E1. Eur J Gastroenterol Hepatol. 2018 Mar 2. doi: 10.1097/MEG.0000000000001105. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 644. | Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference |
| |
Poynard T1,2, Munteanu M3, Charlotte F1, Perazzo H1,2, Ngo Y3, Deckmyn O3, Pais R1,2, Merrouche W4, de Ledinghen V4, Mathurin P4, Ratziu V1,2; for the FLIP Consortium, the FibroFrance-CPAM Group, the FibroFrance-Obese Group. Eur J Gastroenterol Hepatol. 2018 Feb 26. doi: 10.1097/MEG.0000000000001064. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 648. | Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fattyliver disease in severe and morbid obesity |
| |
Ooi GJ1,2, Earnest A3, Kemp WW4, Burton PR5,6, Laurie C5, Majeed A4, Johnson N7, McLean C8, Roberts SK4, Brown WA5,6. Int J Obes (Lond). 2018 Jan 30. doi: 10.1038/s41366-018-0007-3. [Epub ahead of print] |
|
| |
| 649. | Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease |
| |
Rausch JC1, Lavine JE1, Chalasani N2, Guo X3, Kwon S3, Schwimmer JB4, Molleston JP5, Loomba R6, Brunt EM7, Chen YI3, Goodarzi MO8, Taylor KD3, Yates KP9, Rotter JI3; NASH Clinical Research Network. J Pediatr Gastroenterol Nutr. 2018 Feb 21. doi: 10.1097/MPG.0000000000001926. [Epub ahead of print] |
|
| |
| 650. | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease |
| |
Younossi ZM1,2, Stepanova M3,2, Rafiq N1,2, Henry L3,2, Loomba R4, Makhlouf H5, Goodman Z1,2. Hepatol Commun. 2017 Jun 6;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul. |
|
| |
|
|
| |
| 652. | DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis |
| |
Loomba R1, Gindin Y2, Jiang Z2, Lawitz E3, Caldwell S4, Djedjos CS2, Xu R2, Chung C2, Myers RP2, Subramanian GM2, Goodman Z5, Charlton M6, Afdhal NH7, Diehl AM8. JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. [Epub ahead of print] |
|
| |
| 653. | Fructose and sugar: A major mediator of non-alcoholic fatty liver disease |
| |
Jensen T1, Abdelmalek MF2, Sullivan S3, Nadeau KJ4, Green M4, Roncal C3, Nakagawa T5, Kuwabara M3, Sato Y3, Kang DH6, Tolan DR7, Sanchez-Lozada LG8, Rosen HR3, Lanaspa MA3, Diehl AM2, Johnson RJ3. J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30066-7. doi: 10.1016/j.jhep.2018.01.019. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 656. | Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis |
| |
Loffredo L1, Baratta F2, Ludovica P2, Battaglia S2, Carnevale R2, Nocella C2, Novo M2, Pannitteri G3, Ceci F4, Angelico F5, Violi F2, Del Ben M2. Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):143-149. doi: 10.1016/j.numecd.2017.10.027. Epub 2017 Nov 13. |
|
| |
| 657. | Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
| |
Kamada Y1,2, Ono M3, Hyogo H4, Fujii H5, Sumida Y6, Yamada M7, Mori K8, Tanaka S8, Maekawa T1, Ebisutani Y1, Yamamoto A1, Takamatsu S1, Yoneda M6, Kawada N5, Chayama K9, Saibara T3, Takehara T2, Miyoshi E1; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG?NAFLD). Hepatol Commun. 2017 Aug 16;1(8):780-791. doi: 10.1002/hep4.1080. eCollection 2017 Oct. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 664. | A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study |
| |
Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Ma J2, Loomba R6,7,8, Chung RT9, Benjamin EJ2,10,11. Liver Int. 2018 Jan 29. doi: 10.1111/liv.13709. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 680. | Low Circulating Levels of Neurotensin in Women with Nonalcoholic Fatty LiverDisease Associated with Severe Obesity |
| |
Auguet T1,2, Aragonès G1, Berlanga A1, Martínez S3, Sabench F4, Aguilar C1, Villar B2, Sirvent JJ3, Del Castillo D4, Richart C1,2. Obesity (Silver Spring). 2018 Feb;26(2):274-278. doi: 10.1002/oby.22058. Epub 2017 Dec 25. |
|
| |
|
|
| |
|
|
| |
| 683. | Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) |
| |
Tully DC1,2, Rucker PV1, Chianelli D1, Williams J1, Vidal A1, Alper PB1, Mutnick D1, Bursulaya B1, Schmeits J1, Wu X1, Bao D1, Zoll J1, Kim Y1, Groessl T1, McNamara P1, Seidel HM1, Molteni V1, Liu B1, Phimister A2, Joseph SB1, Laffitte B1. J Med Chem. 2017 Dec 28;60(24):9960-9973. doi: 10.1021/acs.jmedchem.7b00907. Epub 2017 Dec 8. |
|
| |
|
|
| |
| 685. | Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma |
| |
Sadler EM1,1, Mehta N1, Bhat M1,1, Ghanekar A1,1, Greig PD1,1, Grant DR1,1, Yao F1, Sapisochin G1,1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002043. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 690. | Impact of steatosis and inflammation definitions on the performance of NASHtests |
| |
Poynard T1,2,3, Munteanu M4, Charlotte F1,2, Perazzo H1,2,3, Ngo Y4, Deckmyn O4, Pais R1,2,3, Mathurin P5, Ratziu V1,2,3; for the FLIP consortium, the FibroFrance-CPAM group; and the FibroFrance-Obese group. Eur J Gastroenterol Hepatol. 2017 Dec 26. doi: 10.1097/MEG.0000000000001033. [Epub ahead of print] |
|
| |
|
|
| |
| 692. | Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid |
| |
Yoo W1, Gjuka D1, Stevenson HL2, Song X3, Shen H1, Yoo SY4, Wang J4, Fallon M5, Ioannou GN6, Harrison SA7, Beretta L1. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017. |
|
| |
|
|
| |
| 694. | Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease |
| |
Eddowes PJ1, McDonald N2, Davies N1, Semple SIK2, Kendall TJ2, Hodson J1, Newsome PN1, Flintham RB1, Wesolowski R1, Blake L1, Duarte RV3, Kelly CJ4, Herlihy AH4, Kelly MD4, Olliff SP1, Hübscher SG1, Fallowfield JA2, Hirschfield GM1. Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14469. [Epub ahead of print] |
|
| |
|
|
| |
| 696. | Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study |
| |
Lee SB1, Park GM2, Lee JY3, Lee BU1, Park JH1, Kim BG1, Jung SW1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1, Yang DH4, Kang JW4, Lim TH4, Kim HK5, Choe J5, Lee HC6. J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32527-8. doi: 10.1016/j.jhep.2017.12.012. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 703. | Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279?013 individuals |
| |
Lauridsen BK1,2, Stender S1,2, Kristensen TS2,3, Kofoed KF2,4, Køber L2,4, Nordestgaard BG2,5,6,7, Tybjærg-Hansen A1,2,5,7. Eur Heart J. 2017 Dec 8. doi: 10.1093/eurheartj/ehx662. [Epub ahead of print] |
|
| |
| 704. | Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial |
| |
Cheng S1,2,3, Ge J4, Zhao C5, Le S6, Yang Y6, Ke D5, Wu N6, Tan X6,7, Zhang X6, Du X4, Sun J8, Wang R5, Shi Y9, Borra RJH10,11, Parkkola R10, Wiklund P7,12,13, Lu D14. Sci Rep. 2017 Nov 21;7(1):15952. doi: 10.1038/s41598-017-16159-x. |
|
| |
| 705. | Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease |
| |
Patel PJ1,2, Smith D3, Connor JP4, Horsfall LU1,2, Hayward KL2, Hossain F5, Williams S5, Johnson T5, Stuart KA1, Brown NN6, Saad N7, Clouston AD2, Irvine KM2,8, Russell AW9,10, Valery PC2,3,9, Powell EE1,2. Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 710. | Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis |
| |
Younossi ZM1, Loomba R2, Anstee QM3, Rinella ME4, Bugianesi E5, Marchesini G6, Neuschwander-Tetri BA7, Serfaty L8, Negro F9, Caldwell SH10, Ratziu V11, Corey KE12, Friedman SL13, Abdelmalek MF14, Harrison SA15, Sanyal AJ16, Lavine JE17, Mathurin P18, Charlton MR19, Goodman ZD1, Chalasani NP9,20, Kowdley KV21, George J22, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721. [Epub ahead of print] |
|
| |
|
|
| |
| 712. | Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) |
| |
Younossi ZM1, Loomba R2, Rinella ME3, Bugianesi E4, Marchesini G5, Neuschwander-Tetri BA6, Serfaty L7, Negro F8, Caldwell SH9, Ratziu V10, Corey KE11, Friedman SL12, Abdelmalek MF13, Harrison SA14, Sanyal AJ15, Lavine JE16, Mathurin P17, Charlton MR18, Chalasani NP19, Anstee QM20, Kowdley KV21, George J22, Goodman ZD1, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724. [Epub ahead of print] |
|
| |
|
|
| |
| 714. | Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study |
| |
Weinstein G1, Zelber-Sagi S1,2, Preis SR3,4, Beiser AS3,4,5, DeCarli C6, Speliotes EK7,8, Satizabal CL4,5, Vasan RS4,5,9, Seshadri S4,5. JAMA Neurol. 2017 Nov 20. doi: 10.1001/jamaneurol.2017.3229. [Epub ahead of print] |
|
| |
| 715. | Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission |
| |
Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2017 Nov 22. pii: dc171590. doi: 10.2337/dc17-1590. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 724. | Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Diseasein a Prospective Study with 1-Year Follow-up : BariScan Study |
| |
Nickel F1, Tapking C1, Benner L2, Sollors J3, Billeter AT1, Kenngott HG1, Bokhary L1, Schmid M1, von Frankenberg M1, Fischer L1, Mueller S3, Müller-Stich BP4. Obes Surg. 2017 Nov 9. doi: 10.1007/s11695-017-3012-z. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 729. | Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet |
| |
Schwenger KJP1,2, Fischer SE2,3, Jackson TD4,5, Okrainec A1,4,5, Allard JP6,7,8. Obes Surg. 2017 Nov 2. doi: 10.1007/s11695-017-2980-3. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 735. | Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey |
| |
Sheridan DA1, Aithal G2, Alazawi W3, Allison M4, Anstee Q5, Cobbold J6, Khan S7, Fowell A8, McPherson S9, Newsome PN10,11, Oben J12, Tomlinson J13, Tsochatzis E14. Frontline Gastroenterol. 2017 Oct;8(4):252-259. doi: 10.1136/flgastro-2017-100806. Epub 2017 Apr 28. |
|
| |
|
|
| |
|
|
| |
| 738. | Steatosis and NASH in type 2 diabetes |
| |
Hu M1, Phan F1, Bourron O2, Ferré P1, Foufelle F3. . Biochimie. 2017 Oct 31. pii: S0300-9084(17)30271-7. doi: 10.1016/j.biochi.2017.10.019. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 741. | Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance |
| |
Baratta F1,2, Pastori D1,2, Polimeni L1, Bucci T3, Ceci F4, Calabrese C1, Ernesti I5, Pannitteri G6, Violi F1, Angelico F7, Del Ben M1. Am J Gastroenterol. 2017 Oct 24. doi: 10.1038/ajg.2017.371. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 747. | Diagnostic Accuracy of Magnetic Resonance Imaging Hepatic Proton Density Fat Fraction in Pediatric Nonalcoholic Fatty Liver Disease |
| |
Middleton MS1, Van Natta ML2, Heba ER1, Alazraki A3, Trout AT4, Masand P5, Brunt EM6, Kleiner DE7, Doo E8, Tonascia J2, Lavine JE9, Shen W9, Hamilton G1, Schwimmer JB10, Sirlin CB1; NASH Clinical Research Network. Hepatology. 2017 Oct 13. doi: 10.1002/hep.29596. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 751. | Developmental Programming of Obesity and Liver Metabolism by Maternal Perinatal Nutrition Involves the Melanocortin System |
| |
Cordero P1, Li J2, Nguyen V3, Pombo J4, Maicas N5, Novelli M6, Taylor PD7, Samuelsson AM8, Vinciguerra M9,10, Oben JA11,12. Nutrients. 2017 Sep 20;9(9). pii: E1041. doi: 10.3390/nu9091041. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 757. | Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects |
| |
Legry V1, Francque S2,3, Haas JT1, Verrijken A3,4, Caron S1, Chávez-Talavera O1, Vallez E1, Vonghia L2,3, Dirinck E4, Verhaegen A4, Kouach M5, Lestavel S1, Lefebvre P1, Van Gaal L3,4, Tailleux A1, Paumelle R1, Staels B1. J Clin Endocrinol Metab. 2017 Aug 4. doi: 10.1210/jc.2017-01397. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 760. | Fatty liver without a large |
| |
Yousef MH1, Al Juboori A1, Albarrak AA1, Ibdah JA1, Tahan V1. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):100-107. doi: 10.4291/wjgp.v8.i3.100. |
|
| |
|
|
| |
| 762. | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
| |
Younossi Z1,2, Anstee QM3,4, Marietti M5, Hardy T3,4, Henry L1,2, Eslam M6, George J6, Bugianesi E5. Nat Rev Gastroenterol Hepatol. 2017 Sep 20. doi: 10.1038/nrgastro.2017.109. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 767. | Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease |
| |
Brady GF1, Kwan R1, Ulintz PJ2, Nguyen P3, Bassirian S3, Basrur V2, Nesvizhskii AI2,4, Loomba R3, Omary MB1. Hepatology. 2017 Sep 13. doi: 10.1002/hep.29522. [Epub ahead of print] |
|
| |
|
|
| |
| 769. | The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial |
| |
Loomba R1, Lawitz E2, Mantry PS3, Jayakumar S4, Caldwell SH5, Arnold H6, Diehl AM7, Djedjos CS8, Han L8, Myers RP8, Subramanian GM8, McHutchison JG8, Goodman ZD9, Afdhal NH10, Charlton MR11; GS-US-384-1497 Investigators. Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 795. | Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease |
| |
Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 801. | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study |
| |
Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 805. | Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery |
| |
Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 816. | Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability |
| |
Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 820. | Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability |
| |
Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 829. | Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH? |
| |
Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
| |
|
|
|
|
|
